クロピドグレルの効用は,STセグメントの上昇のない急性冠動脈症候群の患者に対して,様々なリスクグループにおいて有効である
Andrzej Budaj1, Salim Yusuf, Shamir R Mehta
1Postgraduate Medical School, Grochowski Hospital Warsaw, Poland.
Circulation
|September 25, 2002
まとめ
クロピドグレルは,急性冠動脈症候群の患者の心血管疾患を大幅に軽減します. この利点は,低リスク,中リスク,および高リスクグループ全体で一貫しており,非ST上昇ACSでの使用を支持しています.
科学分野:
- 心臓病学 心臓病学
- クリニック・トライアル 臨床試験
- 薬理学 薬理学とは
背景:
- 不安定性アンギナにおけるクロピドグレルによる再発防止 (CURE) 試験では,非ST上昇性急性冠動脈症候群 (NSTE-ACS) でクロピドグレルのプラセボに対する優位性が確認された.
- アスピリンは,クロピドグレルまたはプラセボと同時に投与された.
研究 の 目的:
- クロピドグレルの治療効果を,将来の心血管疾患に対する患者のリスクの階層化に基づいて評価する.
- CURE試験集団内の異なるリスクカテゴリーにおけるクロピドグレルの有効性を分析する.
主な方法:
- 症状の発症から24時間以内に発症した12,562人の患者がランダムに分けられました.
- 患者は,クロピドグレル (300mgロード,75mg毎日) またはプラセボとアスピリンを3〜12ヶ月間投与された.
- 治療効果は,心筋梗塞における血栓溶解 (Thrombolysis in Myocardial Infarction,TIMI) リスクスコアを使用して分析されました.
主要な成果:
- 心筋梗塞における血栓解離 (Thrombolysis in Myocardial Infarction,TIMI) リスクモデルは,CURE集団で検証されました.
- 主要複合アウトカム (心血管疾患による死亡,心筋梗塞,脳卒中) は,TIMIリスクスコアで増加した.
- クロピドグレルは,低リスク (RR 0.71),中等リスク (RR 0.85),および高リスク (RR 0.73) の各リスクグループにおいて,有意なリスク低下を示した.
結論:
- クロピドグレルは,心血管疾患のリスクに関係なく,急性冠動脈症候群の患者に一貫した利点を提供します.
- この発見は,ST上昇のない急性冠動脈症候群と診断されたすべての患者でクロピドグレルの使用を支持する.
関連する概念動画
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...


